drugset / Trial / NCT04960072
A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)
Phase 0
Recruiting
50 enrolled
Shanghai Juncell Therapeutics
Shanghai 10th People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant refractory/relapsed gastrointestinal tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Timeline
- Start
- 2021-06-30
- Primary completion
- 2025-12-30
- Completion
- 2026-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | 1e+09 cells | Intravenous |
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | 5e+10 cells | Intravenous |